| Literature DB >> 31480542 |
Qingliang Yang1,2, Feng Yuan1, Lei Xu1, Qinying Yan1,2, Yan Yang1,2, Danjun Wu1,2, Fangyuan Guo1,2, Gensheng Yang3,4.
Abstract
Drug hydrolytic degradation, caused by atmospheric and inherent humidity, significantly reduces the therapeutic effect of pharmaceutical solid dosages. Moisture barrier film coating is one of the most appropriate and effective approaches to protect the active pharmaceutical ingredients (API) from hydrolytic degradation during the manufacturing process and storage. Coating formulation design and process control are the two most commonly used strategies to reduce water vapor permeability to achieve the moisture barrier function. The principles of formulation development include designing a coating formulation with non-hygroscopic/low water activity excipients, and formulating the film-forming polymers with the least amount of inherent moisture. The coating process involves spraying organic or aqueous coating solutions made of natural or synthetic polymers onto the surface of the dosage cores in a drum or a fluid bed coater. However, the aqueous coating process needs to be carefully controlled to prevent hydrolytic degradation of the drug due to the presence of water during the coating process. Recently, different strategies have been designed and developed to effectively decrease water vapor permeability and improve the moisture barrier function of the film. Those strategies include newly designed coating formulations containing polymers with optimized functionality of moisture barrier, and newly developed dry coating processes that eliminate the usage of organic solvent and water, and could potentially replace the current solvent and aqueous coatings. This review aims to summarize the recent advances and updates in moisture barrier coatings.Entities:
Keywords: coating formulation; coating method; dry coating; hydrolytic degradation; moisture barrier coating
Year: 2019 PMID: 31480542 PMCID: PMC6781284 DOI: 10.3390/pharmaceutics11090436
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic representation of the moisture uptake.
Polymers used for moisture barrier film coating.
| Type | Trademark | Polymer | Manufacturer |
|---|---|---|---|
| Water-soluble | Opadry® AMB | Polyvinyl alcohol (PVA) | Colorcon |
| Methocel® E3/E5/E6/E15 | Hydroxypropyl methyl cellulose (HPMC) | Dow Chemical (Midland, MI, USA) | |
| Walocel® HM 3 PA/HM 5 PA/HM 6 PA/HM 15 PA | Dow Wolff Cellulosics | ||
| Pharmacoat® 603/606/615/645 | Shin-Etsu (Tokyo, Japan) | ||
| Sepifilm® LP | Seppic (Castres Cedex, France) | ||
| Oxycellulose, Natrosol | Hydroxyethyl cellulose (HEC) | Ashland Aqualon (Covington, Kentucky, USA) | |
| Kollicoat® IR Protect | Polyvinyl alcohol–polyethylene glycol (PVA–PEG copolymer) | BASF (Ludwigshafen, Germany) | |
| Kollicoat® IR | Polyvinyl alcohol–polyethylene glycol (PVA–PEG) | BASF (Ludwigshafen, Germany) | |
| Kollicoat® Smartseal 30D | Methyl methacrylate and diethylamino–ethyl ethacrylate | BASF (Ludwigshafen, Germany) | |
| Klucel™ | Hydroxypropyl cellulose (HPC) | Ashland (Covington, Kentucky, USA) | |
| Insoluble | Kollicoat® SR 30 D | Polyvinyl acetate | BASF (Ludwigshafen, Germany) |
| Auqacoat® ECD | Ethyl cellulose | FMC (Philadelphia, PA, USA) | |
| Surelease® (Fertigprodukt) | Colorcon | ||
| EthocelTM | Dow Chemical (Mitterland, MI, USA) | ||
| Eastman CA | Cellulose acetate | Eastman (Rochester, MN, USA) | |
| Eudragit® RL/ RS 30 D | Ammonio methacrylate | Evonik (Essen, Germany) | |
| Aquapolish® R | Ammonio methacrylate copolymer (type A and type B) | Biogrund (Hünstetten, Germany) | |
| Eudragit® NE 30 D | Poly (ethyl acrylate–co-methyl methacrylate) 2:1 | Evonik (Essen, Germany) | |
| Entero-soluble polymers | SSB 55 Pharma | Shellac | Chineway (Shanghai, China) |
| Aquacoat® CPD | Cellulose acetate phthalate (CAP) | FMC (Philadelphia, PA, USA) | |
| Eastman C-A-P NF | Eastman (Rochester, MN, USA) | ||
| CAB Eastman | Cellulose acetate butyrate (CAB) | Eastman (Rochester, MN, USA) | |
| Eudragit® L30D-55/ L 100-55 | Methacrylic acid copolymer, Type A | Evonik (Essen, Germany) | |
| Eastacryl 30 D NF | Eastman (Rochester, MN, USA) | ||
| Kollicoat® MAE 30 DP/100 P | BASF (Ludwigshafen, Germany) | ||
| Eudragit® L 12.5/ L 100 | Methacrylic acid copolymer, Type B | Evonik (Essen, Germany) | |
| Eudragit® S 12.5/ S 100 | Methacrylic acid copolymer, Type C | Evonik (Essen, Germany) | |
| Eudragit® FS 30 D | Methacrylic acid copolymer | Evonik (Essen, Germany) | |
| Kollicoat® | Amino diethyl–methacrylate copolymer | BASF (Ludwigshafen, Germany) | |
| Eudragit® ®E/ E 12.5 | Amino dimethyl methacrylate copolymer | Evonik (Essen, Germany) | |
| Aquapolish® E | Acrylic acid copolymer | Biogrund (Hünstetten, Germany) | |
| Keltone LV CR | Sodium alginate | FMC (Philadelphia, PA, USA) | |
| Akucell | Carboxymethyl cellulose CMC | Ashland Aqualon (Covington, Kentucky, USA) |
Figure 2Schematic illustration of the film formation process.
Figure 3Schematic diagram of the electrostatic powder coating system.